Médecine

Paramédical

Autres domaines


Suscribirse

Emerging pharmacotherapies for COVID-19 - 18/06/20

Doi : 10.1016/j.biopha.2020.110267 
Rachana Salvi, Panini Patankar
 Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

Corona Virus Disease 19 (COVID 19) is caused by novel corona virus (nCoV) & leads to respiratory failure in susceptible individuals.
Many drugs have been repurposed and are potentially used either prophylactically or therapeutically throughout the world.
SOLIDARITY trial by WHO promotes clinical trial with respect to four potentially useful repurposed medications.
The drugs mentioned in SOLIDARITY trial are mainly antivirals except for hydroxychloroquine which is an anti-malarial drug.
Convalescent plasma therapy is an evolving therapy based on the principle of passive immunity.
Cytokine storm are believed to lead to deterioration in patients and drugs against the same are also in research.

El texto completo de este artículo está disponible en PDF.

Abstract

Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.

El texto completo de este artículo está disponible en PDF.

Keywords : Chloroquine, Hydroxychloroquine, Remdesivir


Esquema


© 2020  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 128

Artículo 110267- août 2020 Regresar al número
Artículo precedente Artículo precedente
  • Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy
  • Yan-Jun Song, Chong-Bin Zhong, Wei Wu
| Artículo siguiente Artículo siguiente
  • Is combined medication with natural medicine a promising therapy for bacterial biofilm infection?
  • Lulu Zhang, Enjun Liang, Yungchi Cheng, Tariq Mahmood, Feng Ge, Ke Zhou, Mei Bao, Lang Lv, Li Li, Jianfeng Yi, Cheng Lu, Yong Tan

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.